Effect of dimethyl fumarate in patients with plaque psoriasis meeting the upgrade criteria required for moderate‐to‐severe disease classification
Abstract Background Oral dimethyl fumarate (DMF) is indicated in patients with plaque psoriasis requiring systemic treatment, including those meeting the upgrade criteria for moderate‐to‐severe disease classification. Objectives To evaluate quality of life (QoL), effectiveness, and tolerability of D...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.504 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|